

### Figure 1. Reprogramming of Somatic Cells In Vivo

(A) Generation of four-factor-inducible ESCs. TetOP, tetracycline-dependent promoter.

(B) Generation of chimeric mice using OSKM-inducible ESCs. mCherry signals could be detected in various organs after Dox treatment for 3 days.

(C) Treatment of chimeric mice with Dox for 28 days resulted in the development of multiple tumors containing pluripotent stem cells. (a) A representative macroscopic image of the cut surface of the kidney tumor. (b) A histological section of the kidney tumor showing the differentiation of tumor cells into three germ layers, indicating teratoma formation. The blue, red, and black arrows represent neuronal, cartilage, and glandular epithelial components, respectively. Scale bar, 200  $\mu$ m.

(legend continued on next page)

and cause neoplasia resembling Wilms tumor, a childhood blastoma in the kidney. Moreover, we demonstrate that altered epigenetic regulations cause the abnormal growth of such failed reprogramming-associated cancer cells.

## RESULTS

### In Vivo Reprogrammable Mouse

To establish the reprogrammable mouse system, we generated embryonic stem cells (ESCs) in which reprogramming factors can be induced under the control of doxycycline (Dox) (Figure 1A) (Carey et al., 2010; Stadtfeld et al., 2010b). We used KH2 ESCs with the optimized reverse tetracycline-dependent transactivator at the *ROSA 26* locus (Beard et al., 2006). A polycistronic cassette encoding four reprogramming factors (*Oct3/4*, *Sox2*, *Klf4*, and *c-Myc*) (Carey et al., 2010), followed by *ires-mCherry*, was targeted into the *Col1a1* gene locus under the tetracycline-dependent promoter of KH2 ESCs (Figure 1A).

Next, we generated chimeric mice via blastocyst injection of four-factor (4F)-inducible ESCs. To confirm inducible expression of the reprogramming factors and mCherry in vivo, Dox-containing water was provided to chimeric mice starting at 4 weeks of age. On day 3 of Dox treatment, we could detect the mCherry signal in various organs, including stomach, intestine, liver, pancreas, kidney, gallbladder, and skin (Figure 1B). We also confirmed the expression of reprogramming factors in germline-transmitted mouse tissues by quantitative RT-PCR (qRT-PCR) (Figure S1A available online).

Mouse embryonic fibroblasts (MEFs) containing these reprogramming factor-inducible alleles could give rise to iPSCs after Dox treatment in vitro (Figure S1B). We next asked whether responding somatic cells could be reprogrammed in vivo. The chimeric and germline-transmitted mice given Dox-containing water (2 mg/ml) from 4 weeks of age became morbid within 7–10 days and a few days, respectively. A small proportion of chimeric mice could be treated with Dox for 4 weeks, presumably because of a lower contribution of ESCs in responding tissues. Notably, mice treated with Dox for 4 weeks developed multiple tumors in several organs, such as the kidney and pancreas (Figure 1Ca), whereas tumor formation was never observed in nontreated mice ( $n = 7$ , 7 months of age). Histological analysis revealed that these tumors differentiated into three different germ layers, indicating that they are teratomas (Figure 1Cb). When teratoma cells were cultured ex vivo in the absence of Dox (no additional 4F expressions), iPSC-like cells were established (Figure 1Da). Importantly, the teratoma-derived iPSC-like cells contributed to adult chimeric mice when they were injected into blastocysts (Figure 1Db). Therefore, we

conclude that somatic cells can be reprogrammed in vivo to pluripotency in our reprogrammable mouse system.

### Forced Expression of Reprogramming Factors In Vivo Leads to Rapid Expansion of Dysplastic Cells

We next examined the early changes after expression of reprogramming factors in somatic cells in vivo. After treatment of 4-week-old mice with Dox for 3–9 days, all mice developed dysplastic lesions in epithelial tissues of various organs (Figure 1E), although there were variations in severity of the phenotype among chimeras. Dysplastic cells proliferated actively, as revealed by Ki67 staining (Figure 1F). Abnormal proliferation of somatic cells was observed as early as 3 days after Dox treatment (Figure S1C), and by day 7, such dysplastic cell growth was detected even for pancreatic and kidney cells, which typically do not divide actively under physiological conditions (Figures 1E and 1F). Immunofluorescent analysis of Oct3/4 and the 2A peptide (forming transgene connections) demonstrated that the dysplastic cells expressed reprogramming factors (Figure 1G). Collectively, the forced expression of reprogramming factors caused dysplastic cell expansion of epithelial tissues in vivo.

### The Fate of Early Dysplastic Cells after Withdrawal of Dox

To examine whether subsequent expansion of such dysplastic cells depends on the continuous expression of reprogramming factors, we withdrew Dox for 7 days after an initial 4- to 7-day treatment (Figure 2A). Although Dox treatment for 4–7 days caused active cell proliferation in a variety of tissues of all mice, we did not observe any dysplastic cells in some mice after withdrawal of Dox (Figure 2A; Table 1). Of particular note, mice treated with Dox for periods less than 5 days before withdrawal often revealed a lack of dysplastic cells (Table 1). These data suggest that early dysplastic cell growth requires continuous expression of reprogramming factors. We next investigated the fate of eliminated dysplastic proliferating cells after the withdrawal of Dox. Bromodeoxyuridine (BrdU) was injected into mice during Dox treatment to label proliferating cells caused by reprogramming factor expression during the first 7 days (Hochedlinger et al., 2005), and then mice were sacrificed after the withdrawal of Dox for 7 days, on day14. Notably, BrdU-labeled cells were often observed in normal-looking pancreatic and kidney tissues at day14 (Figure 2B). Furthermore, BrdU-labeled cells in the pancreatic islets also expressed insulin (Figure 2B). This suggests that the expanded cells caused by the transient expression of reprogramming factors were, at least in part, integrated into normal-looking tissues after Dox withdrawal.


(D) Teratomas contain pluripotent stem cells. (a) Ex vivo teratoma culture gave rise to iPSC-like colonies without Dox exposure. (b) Teratoma-derived iPSCs contributed to adult chimeric mice.

(E) Dysplastic cell expansion by the forced expression of reprogramming factors in vivo. The histology of various organs of mice treated with Dox for 3 to 9 days. Scale bars, 200  $\mu$ m (intestine, skin, pancreas, stomach, and gall bladder) and 100  $\mu$ m (kidney).

(F) Ki67 immunostaining revealed active proliferation of the dysplastic cells in the pancreas and stomach. Scale bars, 200  $\mu$ m.

(G) Immunofluorescent staining for Oct3/4 and 2A peptide in the intestine of an OSKM chimeric mouse treated with Dox for 7 days. The 2A antibody used here recognizes both Oct3/4-P2A and Sox2-T2A. Dysplastic cells showed positive staining for both Oct3/4 and 2A. Scale bar, 50  $\mu$ m.

See also Figure S1.



**Figure 2. Transient Expression of Reprogramming Factors Causes Neoplasia**

(A) A schematic drawing of the experiment and histological sections of the pancreas taken on days 7 and 14. Dysplastic cell growth was induced by treatment with Dox for 7 days (arrows on day 7). The pancreatic section taken on day 14 revealed normal histology. Scale bars, 200  $\mu$ m.

(B) Double immunofluorescence for insulin and BrdU in the pancreas on day 14. For the pulse and chase experiment, BrdU was injected intraperitoneally every day during Dox administration starting on day 2 (days 2–7), followed by withdrawal of Dox for 7 days. BrdU-positive cells were frequently observed in normal-looking pancreatic islet cells, which also expressed insulin. Scale bar, 100  $\mu$ m.

(C) Treatment of OSKM chimeric mice with Dox for 7 days, followed by the withdrawal of Dox for another 7 days. The macroscopic image shows the development of bilateral kidney tumors on day 14. Representative histological images are shown for Dox-withdrawn tumors in the kidney, pancreas, and liver. Scale bars, 200  $\mu$ m.

(legend continued on next page)

**Table 1. Transient Expression of Reprogramming Factors Causes Tumor Development**

Dox Treatment	n	Kidney		Pancreas		Liver	
		No Phenotype	Dysplastic Growth	No Phenotype	Dysplastic Growth	No Phenotype	Dysplastic Growth
4 days ON→OFF	4	2	2	4	0	3	1
5 days ON→OFF	2	1	1	2	0	2	0
6 days ON→OFF	5	1	4	2	3	3	2
7 days ON→OFF	33	7	26	22	11	25	8

### Prolonged Expression of Reprogramming Factors Leads to Transgene-Independent Tumor Formation in Somatic Cells

In contrast to the reversion of early dysplastic proliferating cells into normal-looking cells, mice that had been given Dox for 7 days often went on to develop tumors in multiple responding organs even after Dox withdrawal (Figure 2C; Table 1). The developed tumors consisted of histologically undifferentiated dysplastic cells, which were distinct from teratoma cells (Figures 2C and S2A). The dysplastic cells invaded the surrounding tissues, which is one of the hallmarks of cancer cell growth (Figure S2A). Dox-withdrawn tumor cells were negative for 2A staining, affirming that they grew independent of transgene expression (Figure S2B). Dox-withdrawn kidney tumors were similarly observed in elderly mice given Dox starting at 14 weeks of age (13 out of 19 mice). When Dox-withdrawn kidney tumor cells were transplanted into the subcutaneous tissues of immunocompromised mice, they formed secondary tumors within 3 weeks without Dox administration (Figures 2D and S2C), reflecting the neoplastic potential of Dox-withdrawn tumor cells.

Reprogramming factors in our transgenic system include *c-Myc*, a well-known oncogene. To investigate the contribution of *c-Myc* on the development of Dox-withdrawn tumors, we generated three-factor-inducible chimeric mice, which express *Oct3/4*, *Sox2*, and *Klf4* (OKS), but not *c-Myc*, by the targeted insertion of transgenes into the identical locus as 4F (OSKM)-inducible mice (Figure 2E). Similar to 4F-induced mice, OKS induction in vivo caused dysplastic cell growth in various organs yet required longer periods of treatment (Figure 2E). After 3 weeks of induction of OKS followed by withdrawal for 7 days, these mice developed the Dox-withdrawn tumors consisting of undifferentiated dysplastic cells in multiple organs (4 out of 8 mice; Figure 2E). Therefore, transgenic *c-Myc* is dispensable for the development of Dox-withdrawn tumors.

*Oct3/4* plays a critical role in cellular reprogramming, and expression of three factors (*Klf4*, *c-Myc*, and *Sox2*) in the absence of *Oct3/4* is not sufficient for iPSC generation (Takahashi and Yamanaka, 2006). To further demonstrate a link between

cellular reprogramming and Dox-withdrawn tumor development, we generated chimeric mice in which *Klf4*, *c-Myc*, and *Sox2* (KMS), but not *Oct3/4*, can be induced upon Dox treatment (Figure 2F). Following Dox treatment for 7 days, we observed dysplastic cell growth in the kidney of KMS-inducible mice (three out of six mice; Figure 2F). However, in sharp contrast to OSKM/OKS-induced mice, the withdrawal of Dox eliminated the dysplastic cells in the kidney of KMS-induced mice ( $n = 17$ ; Figure 2F). A previous study demonstrated that ectopic expression of *Oct3/4* alone can induce dysplastic growth whereas the transgene withdrawal leads to complete reversion of such dysplasia (Hochedlinger et al., 2005). Consistent with the previous observation, the *Oct3/4*-single induction under the same experimental condition failed to form Dox-withdrawn tumors ( $n = 18$ ; Figure S2D). Taken together, we conclude that reprogramming pressure toward pluripotency driven by the combination of reprogramming factors is associated with the development of Dox-withdrawn tumors.

### Loss of Cell Identity and Gain of ESC-Related Gene Expression in Dox-Withdrawn Tumors


To characterize Dox-withdrawn tumor cells, we examined gene expression in kidney tumors that arose in OSKM-inducible mice treated with the 7+7– Dox regimen. In the KH2 system, transgene expression in the kidney is induced exclusively in the tubule cells (Beard et al., 2006). We observed decreased expression of kidney tubule cell-specific genes in Dox-withdrawn kidney tumors, indicating loss of kidney cell identity (Figure 3A). A previous study dissected the gene expression signature of ESCs into three functional modules: core pluripotency factors, Polycomb complex factors, and Myc-related factors (Kim et al., 2010). Notably, microarray analysis revealed that the ESC-Core module is similarly activated in Dox-withdrawn kidney tumors and ESCs (Figure 3B) (Ohta et al., 2013). We also found that the Myc module displays similar activation between Dox-withdrawn tumors and ESCs (Figure S3A). The activation of ESC-Core and ESC-Myc modules was similarly confirmed in transplanted secondary tumors (Figure S3B).

(D) Minced Dox-withdrawn tumor cells were injected in the subcutaneous tissues of immunocompromised mice. A histological section of one of the tumors phenocopied the original Dox-withdrawn tumor. Scale bars, 200  $\mu\text{m}$  (upper panel) and 100  $\mu\text{m}$  (lower panel).

(E) A schematic drawing of the OKS transgene at the *Col1a1* locus. A histological section of the kidney on days 21 and 28. The expansion of dysplastic cells was observed in the stomach and kidneys on day 21 (arrows). The dysplastic cell growth could be detected even after the withdrawal of Dox in OKS-induced mice (day 28). Scale bars, 200  $\mu\text{m}$ .

(F) A schematic drawing of the KMS transgene. A histological section of a kidney after the treatment with Dox for 7 days (day 7) and the withdrawal of Dox for another 7 days (day 14). KMS induction leads to dysplastic growth in the kidney tubule cells (arrows for day 7). The inset shows a higher-magnification image. No dysplastic cells were detectable in the kidneys of KMS-induced mice after the withdrawal of Dox (day 14). Scale bars, 200  $\mu\text{m}$ .

See also Figure S2.



**Figure 3. Loss of Cell Identity and Gain of ESC-Related Gene Expression in the Dox-Withdrawn Tumors**

(A) The results of the qRT-PCR analyses of *Aqp1* and *Lrp2*. The expression levels of *Aqp1* and *Lrp2* were significantly downregulated in the Dox-withdrawn kidney tumors. Data are presented as mean  $\pm$  SD. The mean level of normal kidney samples was set to 1.

(B) The microarray analyses revealed the activation of the ESC Core module in Dox-withdrawn kidney tumors.

(C) The results of the qRT-PCR analyses of pluripotency-related genes. Data are presented as mean  $\pm$  SD. The transcript level in ESCs was set to 1.

(D) *Lgr5* as a candidate marker of Dox-withdrawn kidney tumor cells. *Lgr5* was specifically expressed in Dox-withdrawn kidney tumors. Data are presented as mean  $\pm$  SD. The mean level of kidney tumors was set to 1.

(E) A schematic drawing of the experimental protocol using chimeric mice with both reprogrammable alleles and the *Lgr5-EGFP* allele. Macroscopic images of the Dox-withdrawn kidney tumor with the *Lgr5-EGFP* allele showing scattered EGFP signals in the kidney tumor. GFP immunostaining of kidney tumor sections revealed that the GFP signals are detectable specifically in tumor cells. Scale bar, 100  $\mu$ m.

(legend continued on next page)

Some pluripotency-related genes, including *Nanog*, *Oct3/4*, and *Lin28a*, were upregulated in the Dox-withdrawn kidney tumor cells as compared to normal kidney tissue, although the expression levels of both *Nanog* and endogenous *Oct3/4* were significantly lower than that of pluripotent stem cells (Figures 3C and S3C). Conversely, other pluripotency-related genes, such as *Esrrb*, were not upregulated in these tumors (Figures 3C).

To further characterize Dox-withdrawn tumor cells, we sought to identify tumor-cell-specific markers. We found that *Lgr5* is specifically upregulated in Dox-withdrawn kidney tumor cells, but not in adult kidney tissues or pluripotent stem cells (Figure 3D). Increased expression of *Lgr5* was similarly observed in the transplanted secondary tumors (Figure S3D). Therefore, we established iPSC lines from OSKM-inducible MEFs containing *Lgr5*-EGFP reporter allele in which *Lgr5* expression can be visualized by enhanced green fluorescent protein (EGFP) (Barker et al., 2007). The established *Lgr5*-reporter iPSCs do not express EGFP in ESC culture conditions (Figure S3E). OSKM-inducible *Lgr5* reporter chimeric mice at 4 weeks of age were treated with the 7+/7– Dox regimen. Again, these mice developed Dox-withdrawn kidney tumors consisting of dysplastic cells (Figure 3E). The scattered EGFP signals were observed in kidney tumors (Figure 3E), and immunohistochemical analysis revealed that *Lgr5* is specifically expressed in part of Dox-withdrawn kidney tumor cells (Figures 3E and S3E). These findings indicate that Dox-withdrawn kidney tumors contain *Lgr5*-positive cells and that the *Lgr5* reporter allele is available to specifically identify the Dox-withdrawn kidney tumor cells that are distinct from fully reprogrammed pluripotent stem cells. Of note, some of the *Lgr5*-expressing tumor cells also expressed *Oct3/4* and *Lin28b* in immunohistochemical analysis (Figures 3F and S3F), thus suggesting that *Lgr5*-expressing tumor cells share some characteristics with pluripotent stem cells. The fact that Dox treatment for longer than 8 days followed by Dox withdrawal often results in teratoma formation supports the notion that partial reprogramming toward pluripotent stem cells is involved in the development of Dox-withdrawn tumors (data not shown). Altogether, our findings indicate that *Lgr5*-expressing tumor cells are distinct from pluripotent stem cells but contain partially reprogrammed cells.

#### Failed Repression of ESC-Polycomb Targets in Dox-Withdrawn Tumors

In contrast to ESC-like activation observed for both the ESC-Core and ESC-Myc modules, the ESC Polycomb repressive complex (PRC) module was differentially expressed between Dox-withdrawn tumors and ESCs (Figure 4A). We found that a number of ESC-PRC targeted genes are not repressed in both kidney tumors and transplanted secondary tumors (Figures 4A, S4A, and S4B), indicating that the failed repression of ESC-PRC targets is associated with the development of Dox-with-


drawn tumors. Consistent with the notion, more than one-fourth of the upregulated genes in tumor cells as compared to ESCs (greater than 3-fold upregulation) were targets of PRC in ESCs (Mikkelsen et al., 2007) (Table S1). We also found that Dox-withdrawn kidney tumors express kidney-precursor-expressing genes such as *Six2*, *Eya1*, and *Lgr5* (Barker et al., 2012; Kobayashi et al., 2008) (Figures 4B and S4C). In particular, *Six2* and *Lgr5*, which are also PRC targets in ESCs (Mikkelsen et al., 2007), are specifically upregulated in both Dox-withdrawn kidney tumors and secondary tumors when compared to both normal kidney tissues and pluripotent stem cells (Figures 3D, 4B, S3D, and S4D). Chromatin immunoprecipitation (ChIP)-qPCR experiments confirmed decreased H3K27me3 levels at both *Six2* and *Lgr5* promoter regions in Dox-withdrawn tumors when compared with those in normal kidney tissues (Figure S4E). Failed repression of the ESC-PRC module was also detectable in unsuccessfully reprogrammed kidney cells in vitro, which were established by the transient expression of reprogramming factors in isolated kidney tubule cells in vitro (Figure S4F).

We next examined the kinetics of transcriptional changes during the development of the Dox-withdrawn tumors. Immunohistochemical analysis revealed that early dysplastic cells at day 7 coincide with transgene-expressing cells (Figure S4G). Taking advantage of fluorescence-linked transgene expression in our mice, we fluorescence-activated cell sorted mCherry-positive kidney cells in OSKM mice given Dox for 7 days (D7), isolating early dysplastic cells for gene expression analysis. Fluorescence-activated cell-sorted D7 LacZ-mCherry-expressing kidney cells were used as a control (Figure S4H). Decreased expression of proximal tubule cell markers was observed in the D7 OSKM cells as compared to D7 LacZ cells, suggesting that the loss of kidney cell identity occurs in early dysplastic cells (Figure S4I). In contrast, increased expression of ectopic stem/progenitor cell markers was not evident in D7 OSKM cells (Figure S4I). These findings suggest that remodeling of global transcriptional profiles toward a stem/progenitor-like state is specifically associated with transgene-independent, late dysplastic cells.

To investigate cell-of-origin effects on failed reprogramming, we next performed a microarray analysis for Dox-withdrawn liver tumors and compared the data with that of kidney tumors. As observed in kidney tumors, the liver tumors displayed failed repression of the ESC-PRC module, accompanied by activation of both the ESC-Core and Myc modules (Figure S4J; Table S1). Although derepressed PRC module genes in kidney tumors and liver tumors often overlapped (Figure S5A; Table S1), we found differentially derepressed PRC genes between kidney and liver tumors. Notably, such differentially derepressed PRC genes were associated with kidney and liver development, respectively. These findings suggest that failed PRC repression in Dox-withdrawn tumors may be associated with the activation of a developmental transcription

(F) Dox-withdrawn tumors express pluripotency-related proteins. Double immunofluorescence for *Lin28b* and GFP (*Lgr5*) revealed that the GFP-positive tumor cells also expressed *Lin28b*. Double immunofluorescence for *Oct3/4* and GFP (*Lgr5*) showed that a subset of GFP-positive tumor cells expressed *Oct3/4* in the nucleus. Scale bars, 20  $\mu$ m.

See also Figure S3.



**Figure 4. Altered Epigenetic Regulation in Dox-Withdrawn Tumors**

(A) The microarray analyses revealed that ESC-PRC target genes were often activated in Dox-withdrawn kidney tumors compared to normal kidney tissues. (B) *Six2* was highly expressed only in the Dox-withdrawn kidney tumors. Data are presented as mean  $\pm$  SD. The mean level of kidney tumors was set to 1. (C) Altered DNA methylation patterns in Dox-withdrawn tumors and the DNA methylation status of representative genes in the RRBS analyses. (D) The global analyses for the DNA methylation levels. Genes that were differentially methylated between ESCs and normal kidney samples (more than 30% difference) were extracted and then analyzed for DNA methylation levels in Dox-withdrawn kidney tumors. Kidney tumors gain DNA methylation at ESC-methylated genes, whereas kidney-methylated genes often retain their methylation status in kidney tumors.

(legend continued on next page)

program, which is affected in part by the cell of origin (Figure S5A).

### Altered DNA Methylation in Dox-Withdrawn Kidney Tumor Cells

Somatic cell reprogramming is accompanied by global changes in DNA methylation patterns (Mikkelsen et al., 2008). The fact that failed reprogramming can cause tumor development suggests that altered epigenetic modifications play a role in tumorigenesis. To quantitatively profile DNA methylation in Dox-withdrawn tumors, we next performed reduced representation bisulfite sequencing (RRBS) (Meissner et al., 2005). We identified a number of genes with altered DNA methylation levels in Dox-withdrawn tumors as compared to normal kidney tissues. Dox-withdrawn tumors revealed frequent gains of DNA methylation at DNA-methylated genes in ESCs, whereas loss of methylation at DNA-methylated genes in kidney tissues was not evident (Figure 4C). To validate these findings, we next performed a global analysis. We first extracted genes differentially methylated between ESCs and normal kidney samples and then examined their DNA methylation in Dox-withdrawn tumors. The global analysis confirmed that Dox-withdrawn kidney tumors gained de novo methylation at ESC-methylated genes, whereas kidney-methylated genes often retain their methylation in Dox-withdrawn kidney tumors (Figure 4D). Consistent with these findings, ESC-methylated genes were frequently found to be repressed in Dox-withdrawn tumors, whereas kidney-methylated genes tended to remain silent in these tumors (Figure 4E). These results suggest that loss of somatic cell-specific DNA methylation is preceded by a gain of ESC-specific DNA methylation patterns during the reprogramming process.

Adult cancers generally exhibit two distinct patterns of alterations in DNA methylation: site-specific DNA hypermethylation and global DNA hypomethylation (Jones and Baylin, 2002; Yamada et al., 2005). We performed specified regional analyses for the DNA methylation in normal kidney tissues and Dox-withdrawn kidney tumors. DNA hypermethylation at promoter regions in Dox-withdrawn tumors was not detectable, regardless of the presence of CpG islands (Figure S5B). Additionally, decreased DNA methylation levels at intergenic regions were not obvious in Dox-withdrawn tumors (Figure S5B).

We found that Dox-withdrawn kidney tumors aberrantly express a number of imprinted genes and that altered expression levels are similar to those in ESCs (Figure S5C). When DNA methylation status at differentially methylated regions (DMRs) of imprinted genes were examined in Dox-withdrawn tumors using a MassARRAY platform (Ehrich et al., 2005), we found frequent alterations of DNA methylation status at DMRs in Dox-withdrawn tumors (Figure S5D). The aberrant genomic methylation levels at imprinted genes in Dox-withdrawn tumors

were also confirmed by RRBS analysis (Figures 4F and S5E). Intriguingly, each Dox-withdrawn tumor revealed variable aberrations in DNA methylation at different imprinted genes. The aberrant methylation includes hypermethylation at the *Meg3* (*Gtl2*) DMR, which has been correlated with impaired differentiation properties of iPSCs (Stadtfield et al., 2010a) (Figures 4F and S5E). Moreover, SNP analysis in the hybrid KH2 background revealed that the altered expression of some imprinted genes in Dox-withdrawn tumors arise from biallelic transcription, compared to monoallelic expression in the original OSKM-inducible ESCs (Figure S5F). Collectively, these results suggest that genomic imprinting is unstable in Dox-withdrawn tumors and provide additional evidence that altered gene expression underlying tumor development is associated with altered epigenetic signatures.

### Dox-Withdrawn Kidney Tumors Resemble Wilms Tumors

Histological analysis revealed that Dox-withdrawn kidney tumors in reprogrammable mice resemble Wilms tumor, the most common pediatric kidney cancer (Figure 5A). A number of studies demonstrated that increased expression of *Igf2* with DNA hypermethylation at the *H19* DMR is one of the causative and most common alterations in Wilms tumors (Ogawa et al., 1993; Steenman et al., 1994). We confirmed that Dox-withdrawn tumors express a significantly higher level of *Igf2* than noninduced tissues (Figures 5B and S6A). Moreover, consistent with altered DNA methylation at other imprinted genes, the increased methylation at the *H19* DMR was detectable in some Dox-withdrawn kidney tumors (Figure 5C).


To additionally evaluate the similarity between Dox-withdrawn kidney tumors and Wilms tumors, we next compared global gene expression patterns. We first selected genes that are upregulated more than 5-fold in Dox-withdrawn kidney tumors in comparison with noninduced kidney tissues and then assessed expression of their human orthologs in human normal kidney tissues, Wilms tumors, and human ESCs (hESCs) using previously reported microarray data sets (Tchieu et al., 2010; Yussenko et al., 2009). We found that upregulated genes in Dox-withdrawn kidney tumors are frequently upregulated in both Wilms tumors and hESCs as compared to normal kidney samples (Figure 5D), whereas this upregulation is not evident in adult kidney cancers (renal cell carcinomas [RCCs]) (Figure S6B).

We also analyzed the expression of genes in ESC-Core, ESC-Myc, and ESC-PRC modules in Wilms tumors. Notably, ESC-upregulated genes in both ESC-Core and ESC-Myc modules are similarly activated in Wilms tumors (Figures 5D and S6C), although *NANOG* and *OCT3/4* are not expressed in Wilms tumors. In contrast, a fraction of ESC-PRC targeted genes expressed in kidney progenitors, such as *SIX2* and *LGR5*, are specifically upregulated in Wilms tumors as compared with

(E) DNA-methylation-associated gene regulation in Dox-withdrawn tumors. The vast majority of ESC-methylated genes were downregulated in Dox-withdrawn tumors, whereas a significant portion of kidney-methylated genes remained repressed in these tumors. ESC-methylated genes with decreased expression levels in ESCs and kidney-methylated genes with decreased expression levels in the kidney tissues were examined.

(F) Altered DNA methylation at the DMR of imprinting genes. Note that kidney tumor 2 showed aberrant methylation patterns at *Nnat*, *Impact*, and *Meg3*. In contrast, kidney tumor 1 showed an aberration only at *Nnat*. See also Figures S4 and S5.





**Figure 5. Dox-Withdrawn Kidney Tumors Resemble Wilms Tumors**

(A) Representative histological findings of Dox-withdrawn kidney tumors (a–d). Tumors consisted of epithelial (b), stromal (c), and blastema-like (d) compartments, which are histological features of Wilms tumors. Scale bars, 500  $\mu\text{m}$  (a) and 100  $\mu\text{m}$  (b–d).

(B) The results of the qRT-PCR analysis for *Igf2*. *Igf2* was highly expressed in Dox-withdrawn kidney tumors. Data are presented as mean  $\pm$  SD. The mean level of kidney tumors was set to 1.

(legend continued on next page)

those in normal kidney tissues, hESCs, and RCCs (Figures 5D and S6D) (Aiden et al., 2010). Collectively, kidney tumors induced by the transient expression of reprogramming factors display a number of shared characteristics with Wilms tumor. These findings also indicate that our mouse model may prove useful to uncover the pathogenesis of Wilms tumors.

### iPSCs Derived from Dox-Withdrawn Kidney Tumors Contribute to Nonneoplastic Kidney Tissues in Chimeric Mice

We next tried to establish iPSCs from Dox-withdrawn kidney tumor cells. The tumor cell-specific *Lgr5-EGFP* reporter allele defined in this study was utilized to isolate tumor cells (Figures 3D, 3E, and S3E). *Lgr5*-expressing GFP-positive tumor cells were sorted and cultured in vitro with Dox to establish iPSCs from tumor cells (Figure 6A). During the culture of *Lgr5*-expressing tumor cells in vitro, *Nanog* expression at a level comparable to that in pluripotent stem cells was detected as early as 7 days after reprogramming factor induction (Figure 6B), a rate faster than the reprogramming process from normal kidney tubule cells in vitro (Figure S7A). After 2 weeks of culture with Dox exposure, more than 20 alkaline phosphatase (AP)-positive iPSC-like colonies were obtained from 100 *Lgr5*-expressing tumor cells (Figure S7B). We were able to establish Dox-independent iPSC lines from tumor cells at 3 weeks after transgene induction (Figure 6C), suggesting that the Dox-withdrawn tumor cells can be readily reprogrammed into pluripotent stem cells.

Cancers are believed to arise through the accumulation of multiple genetic abnormalities. We next investigated whether genetic abnormalities mandate the emergence of in Dox-withdrawn tumors. Exonic regions of 514 genes that include human-cancer-related genes in transplanted secondary kidney tumors were sequenced using a hybridization selection technique combined with next-generation sequencing (Table S3). Mutations in *Wt1*, *Wtx*, *Cttnb1*, and *Trp53*, all of which have been identified in a subset of Wilms tumors, were not detected in three tumors examined. In addition, no cancer-related gene mutations were enriched in these tumors (data not shown). Array-based comparative genomic hybridization (CGH) revealed no prevalent chromosomal alteration in tumor samples (Figure S7C).

Finally, we injected the tumor-derived iPSCs into blastocysts to generate chimeric mice. Tumor-derived iPSCs contributed into adult chimeric mice (Figure 6D). Notably, the kidney-tumor-derived iPSCs differentiated into normal-looking kidney tissues (Figures 6E, 6F, and S7D). Moreover, these chimeric mice did not develop tumors even at 24 weeks of age ( $n = 8$ ). To further demonstrate that tumorigenic cells can be reprogrammed into nonneoplastic cells, we also established iPSCs from the transplanted secondary tumors and confirmed their contribution to nonneoplastic kidney tissues (Figure S7E). These results substantiate that a genetic context of the Dox-withdrawn kidney tumor cells is not determinant of the cancer phenotype and

support the conclusion that altered epigenetic regulations cause the abnormal growth in somatic cells, leading to the development of Dox-withdrawn tumors.

### DISCUSSION

During somatic cell reprogramming, iPSCs gain the capacity for unlimited growth without particular genetic alterations. Using abbreviated reprogramming factor expression in vivo, we demonstrate that transient expression of reprogramming factors leads to tumor development. Such tumors display altered epigenetic modifications, indicating that epigenetic regulation characteristic of cellular reprogramming may also confer neoplastic growth properties to somatic cells. Intriguingly, Dox-withdrawn tumor cells are readily reprogrammed into pluripotent stem cells by additional 4F expression, indicating that the tumor cells represent a cellular state closer to iPSCs than the original somatic cells. Moreover, kidney tumor cell-derived iPSCs contribute to various somatic cell types and give rise to nonneoplastic kidney cells in mice. These data demonstrate that the abnormal growth of unsuccessfully reprogrammed cells depends predominantly on epigenetic regulations and raise the possibility that particular types of cancer may arise exclusively through altered epigenetic regulation.

Histological features of Dox-withdrawn tumors imply that unsuccessfully reprogrammed cells lack the ability to terminal differentiate along multiple lineages. It is noteworthy that Dox-withdrawn tumor cells fail to repress ESC-PRC targets yet share the activation of ESC core regulatory circuitry and Myc-related genes with pluripotent stem cells. It is conceivable that the repression of ESC-PRC targets would be exclusively associated with the acquisition of pluripotency, whereas activation of ESC core regulatory circuitry and Myc targets lead to self-renewing activity. This notion is also consistent with previous findings that PRC components are important for successful reprogramming in humans (Onder et al., 2012). Notably, the failed repression of the ESC-PRC module was detectable in previously reported partially reprogrammed cells in vitro (Polo et al., 2012), in which the activation of both ESC-Core and ESC-Myc modules had already occurred (Figure S7F). We also found that unsuccessfully reprogrammed kidney cells tend to retain DNA methylation at kidney-specific methylated genes. Considering that global epigenetic reorganization, including changes in both H3K27 methylation and DNA methylation, occurs during the later phase of iPSC generation (Polo et al., 2012), the expected repression of ESC-PRC targets and demethylation of somatic cell-specific genomic methylation might play a role in the final stages of successful somatic cell reprogramming.

Recently, Abad et al. reported that in vivo reprogramming allows the acquisition of totipotent features resulting in embryo-like cyst formation in reprogrammable mice (Abad et al., 2013). However, in the present study, we did not observe such cystic structures in Dox-treated reprogrammable mice.

(C) The bisulfite sequencing analysis revealed increased DNA methylation levels at the *H19* DMR containing two CTCF binding sites in Dox-withdrawn tumors. (D) The results of the global expression analyses in Wilms tumors. The human orthologs of upregulated genes in Dox-withdrawn tumors and ESC module genes were assessed using previously reported microarray data sets (GSE11151 and GSE22246). See also Figure S6.